Switch theme
Sign up to access all valuation multiples
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
2000
767
LTM Revenue $389M
LTM EBITDA $138M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anhui Anke Biotechnology has a last 12-month revenue (LTM) of $389M and a last 12-month EBITDA of $138M.
In the most recent fiscal year, Anhui Anke Biotechnology achieved revenue of $352M and an EBITDA of $129M.
Anhui Anke Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anhui Anke Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $389M | XXX | $352M | XXX | XXX | XXX |
| Gross Profit | $303M | XXX | $272M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | $138M | XXX | $129M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 37% | XXX | XXX | XXX |
| EBIT | $123M | XXX | $110M | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $110M | XXX | $98.1M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anhui Anke Biotechnology's stock price is CNY 9 (or $1).
Anhui Anke Biotechnology has current market cap of CNY 14.9B (or $2.1B), and EV of CNY 13.7B (or $1.9B).
See Anhui Anke Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.1B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anhui Anke Biotechnology has market cap of $2.1B and EV of $1.9B.
Anhui Anke Biotechnology's trades at 5.4x EV/Revenue multiple, and 14.8x EV/EBITDA.
Equity research analysts estimate Anhui Anke Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anhui Anke Biotechnology has a P/E ratio of 18.8x.
See valuation multiples for Anhui Anke Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBIT | 15.5x | XXX | 17.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.8x | XXX | 21.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 24.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnhui Anke Biotechnology's last 12 month revenue growth is 21%
Anhui Anke Biotechnology's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Anhui Anke Biotechnology's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anhui Anke Biotechnology's rule of X is 88% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anhui Anke Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 57% | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 88% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anhui Anke Biotechnology acquired XXX companies to date.
Last acquisition by Anhui Anke Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Anhui Anke Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anhui Anke Biotechnology founded? | Anhui Anke Biotechnology was founded in 2000. |
| Where is Anhui Anke Biotechnology headquartered? | Anhui Anke Biotechnology is headquartered in China. |
| How many employees does Anhui Anke Biotechnology have? | As of today, Anhui Anke Biotechnology has 767 employees. |
| Is Anhui Anke Biotechnology publicy listed? | Yes, Anhui Anke Biotechnology is a public company listed on SHE. |
| What is the stock symbol of Anhui Anke Biotechnology? | Anhui Anke Biotechnology trades under 300009 ticker. |
| When did Anhui Anke Biotechnology go public? | Anhui Anke Biotechnology went public in 2009. |
| Who are competitors of Anhui Anke Biotechnology? | Similar companies to Anhui Anke Biotechnology include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's current market cap is $2.1B |
| What is the current revenue of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12 months revenue is $389M. |
| What is the current revenue growth of Anhui Anke Biotechnology? | Anhui Anke Biotechnology revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Anhui Anke Biotechnology? | Current revenue multiple of Anhui Anke Biotechnology is 4.9x. |
| Is Anhui Anke Biotechnology profitable? | Yes, Anhui Anke Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12 months EBITDA is $138M. |
| What is Anhui Anke Biotechnology's EBITDA margin? | Anhui Anke Biotechnology's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Anhui Anke Biotechnology? | Current EBITDA multiple of Anhui Anke Biotechnology is 13.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
